From mice to men and back

An assessment of preclinical model systems for the study of lung cancers

Adi F. Gazdar, Fred R. Hirsch, John D. Minna

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Introduction: Studies of preclinical models are essential for determining the biology of lung cancers and testing new and novel therapeutic approaches. We review the commonly used preclinical models for lung cancers and evaluate their strengths and weaknesses. Methods: We searched the MEDLINE database via PubMed using combinations of the following medical subject headings: lung cancer; animal models, mice; cell line, tumor; cell culture, mice; transgenic, mice; SCID, transplantation; heterologous; and genetic engineering. We reviewed the relevant published articles. Results: Multiple examples of the three major preclinical models-tumor cell lines, patient-derived xenografts, and genetically engineered mouse models-exist and have been used by investigators worldwide, with more than 15,000 relevant publications. Each model has its strengths and actual or potential weaknesses. In addition, newer forms of these models have been proposed or are in use as potential improvements over the conventional models. Conclusions: A large number and variety of models have been developed and extensively used for the study of all major types of lung cancer. While they remain the cornerstone of preclinical studies, each model has its individual strengths and weaknesses. These must be carefully evaluated and applied to the proposed studies to obtain the maximum usefulness from the models.

Original languageEnglish (US)
Pages (from-to)287-299
Number of pages13
JournalJournal of Thoracic Oncology
Volume11
Issue number3
DOIs
StatePublished - Mar 23 2016

Fingerprint

Lung Neoplasms
Tumor Cell Line
Medical Subject Headings
Genetic Engineering
Heterografts
PubMed
MEDLINE
Transgenic Mice
Publications
Animal Models
Cell Culture Techniques
Transplantation
Research Personnel
Databases
Therapeutics

Keywords

  • Cell lines
  • Cell Lines
  • Genetically Engineered Mouse Models
  • Lung Cancer
  • Neuroendocrine Carcinomas
  • Non-Small Cell Lung Cancer
  • Patient-Derived Xenografts
  • Preclinical Models
  • Small Cell Lung Cancer

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

From mice to men and back : An assessment of preclinical model systems for the study of lung cancers. / Gazdar, Adi F.; Hirsch, Fred R.; Minna, John D.

In: Journal of Thoracic Oncology, Vol. 11, No. 3, 23.03.2016, p. 287-299.

Research output: Contribution to journalArticle

@article{d35b8085a3ae446fa121fffe538352d3,
title = "From mice to men and back: An assessment of preclinical model systems for the study of lung cancers",
abstract = "Introduction: Studies of preclinical models are essential for determining the biology of lung cancers and testing new and novel therapeutic approaches. We review the commonly used preclinical models for lung cancers and evaluate their strengths and weaknesses. Methods: We searched the MEDLINE database via PubMed using combinations of the following medical subject headings: lung cancer; animal models, mice; cell line, tumor; cell culture, mice; transgenic, mice; SCID, transplantation; heterologous; and genetic engineering. We reviewed the relevant published articles. Results: Multiple examples of the three major preclinical models-tumor cell lines, patient-derived xenografts, and genetically engineered mouse models-exist and have been used by investigators worldwide, with more than 15,000 relevant publications. Each model has its strengths and actual or potential weaknesses. In addition, newer forms of these models have been proposed or are in use as potential improvements over the conventional models. Conclusions: A large number and variety of models have been developed and extensively used for the study of all major types of lung cancer. While they remain the cornerstone of preclinical studies, each model has its individual strengths and weaknesses. These must be carefully evaluated and applied to the proposed studies to obtain the maximum usefulness from the models.",
keywords = "Cell lines, Cell Lines, Genetically Engineered Mouse Models, Lung Cancer, Neuroendocrine Carcinomas, Non-Small Cell Lung Cancer, Patient-Derived Xenografts, Preclinical Models, Small Cell Lung Cancer",
author = "Gazdar, {Adi F.} and Hirsch, {Fred R.} and Minna, {John D.}",
year = "2016",
month = "3",
day = "23",
doi = "10.1016/j.jtho.2015.10.009",
language = "English (US)",
volume = "11",
pages = "287--299",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "3",

}

TY - JOUR

T1 - From mice to men and back

T2 - An assessment of preclinical model systems for the study of lung cancers

AU - Gazdar, Adi F.

AU - Hirsch, Fred R.

AU - Minna, John D.

PY - 2016/3/23

Y1 - 2016/3/23

N2 - Introduction: Studies of preclinical models are essential for determining the biology of lung cancers and testing new and novel therapeutic approaches. We review the commonly used preclinical models for lung cancers and evaluate their strengths and weaknesses. Methods: We searched the MEDLINE database via PubMed using combinations of the following medical subject headings: lung cancer; animal models, mice; cell line, tumor; cell culture, mice; transgenic, mice; SCID, transplantation; heterologous; and genetic engineering. We reviewed the relevant published articles. Results: Multiple examples of the three major preclinical models-tumor cell lines, patient-derived xenografts, and genetically engineered mouse models-exist and have been used by investigators worldwide, with more than 15,000 relevant publications. Each model has its strengths and actual or potential weaknesses. In addition, newer forms of these models have been proposed or are in use as potential improvements over the conventional models. Conclusions: A large number and variety of models have been developed and extensively used for the study of all major types of lung cancer. While they remain the cornerstone of preclinical studies, each model has its individual strengths and weaknesses. These must be carefully evaluated and applied to the proposed studies to obtain the maximum usefulness from the models.

AB - Introduction: Studies of preclinical models are essential for determining the biology of lung cancers and testing new and novel therapeutic approaches. We review the commonly used preclinical models for lung cancers and evaluate their strengths and weaknesses. Methods: We searched the MEDLINE database via PubMed using combinations of the following medical subject headings: lung cancer; animal models, mice; cell line, tumor; cell culture, mice; transgenic, mice; SCID, transplantation; heterologous; and genetic engineering. We reviewed the relevant published articles. Results: Multiple examples of the three major preclinical models-tumor cell lines, patient-derived xenografts, and genetically engineered mouse models-exist and have been used by investigators worldwide, with more than 15,000 relevant publications. Each model has its strengths and actual or potential weaknesses. In addition, newer forms of these models have been proposed or are in use as potential improvements over the conventional models. Conclusions: A large number and variety of models have been developed and extensively used for the study of all major types of lung cancer. While they remain the cornerstone of preclinical studies, each model has its individual strengths and weaknesses. These must be carefully evaluated and applied to the proposed studies to obtain the maximum usefulness from the models.

KW - Cell lines

KW - Cell Lines

KW - Genetically Engineered Mouse Models

KW - Lung Cancer

KW - Neuroendocrine Carcinomas

KW - Non-Small Cell Lung Cancer

KW - Patient-Derived Xenografts

KW - Preclinical Models

KW - Small Cell Lung Cancer

UR - http://www.scopus.com/inward/record.url?scp=84962522570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962522570&partnerID=8YFLogxK

U2 - 10.1016/j.jtho.2015.10.009

DO - 10.1016/j.jtho.2015.10.009

M3 - Article

VL - 11

SP - 287

EP - 299

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 3

ER -